Company news

Myriad Genetics, Inc. news in 2019

Myriad Genetics, Inc.'s news releases, calls and decks from 2019, newest first.

View company

Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer

December 29, 2019

Myriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes

December 13, 2019

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening

December 3, 2019

Myriad Genetics Announces Regulatory Approval of the BRACAnalysis® Diagnostic System in Japan for Breast Cancer Patients

November 20, 2019

Myriad’s Prequel™ Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening

November 10, 2019

Myriad Genetics Reports Fiscal First-Quarter 2020 Financial Results

November 3, 2019

Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting

October 31, 2019

Myriad to Announce Fiscal First-Quarter 2020 Financial Results on November 4, 2019

October 29, 2019

Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting

October 27, 2019

FDA Approves Myriad’s myChoice® CDx Test to Help Identify Women Eligible for Treatment with Zejula® in Late-line Ovarian Cancer

October 22, 2019

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience

October 20, 2019

Myriad Genetics Expands Board of Directors with Two Additional Members

September 24, 2019

Myriad Announces Research Collaboration with University of Leeds

September 15, 2019

Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test

April 8, 2019

Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership

April 3, 2019

Decks in 2019